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Context: 
Maternal gestational diabetes (GDM) and pre-pregnancy overweight/obesity (body mass 
index, BMI ≥25kg/m2) may adversely affect offspring cardio-metabolic health. 
Objective: 
To assess associations of maternal GDM and pre-pregnancy overweight/obesity with adult 
offspring cardio-metabolic risk factors. 
Design: 
Longitudinal cohort study (ESTER and AYLS). 
Setting: 
Province of Uusimaa and Northern Finland. 
Participants: 
At mean age 24.1 years (SD 1.3), we classified offspring to offspring of mothers with 1) 
GDM regardless of pre-pregnancy BMI (OGDM; n=193), 2) normoglycemic mothers with 
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pre-pregnancy overweight/obesity (ONO, n=157) and 3) normoglycemic mothers with pre-
pregnancy BMI<25kg/m2 (controls, n=556). 
Main Outcome Measures: 
We assessed cardio-metabolic biomarkers from blood and measured resting blood pressure 
and heart rate. 
Results: 
Compared with controls, OGDM and ONO had higher fasting glucose [1.6% (95% 
confidence interval 0.1, 3.1)]; [2.3% (0.5, 4.3), respectively]; and insulin [12.7% (4.4, 21.9)]; 
[8.7% (0.2, 17.8)]. These differences attenuated to non-significance when adjusted for 
confounders and/or current offspring characteristics including BMI or body fat percentage. 
OGDM showed lower sex hormone binding globulin [SHBG; men: -12.4% (-20.2, -3.9), 
women: -33.2% (-46.3, -16.8)], high-density lipoprotein [-6.6% (-10.9, -2.2)] and 
apolipoprotein A1 [-4.5% (-7.5, -1.4), these differences survived the aforementioned 
adjustments. Heart rate and other biomarkers were similar between groups. 
Conclusions: 
Adult offspring of mothers with GDM have increased markers of insulin resistance and a 
more atherogenic lipid profile; these are only partly explained by confounders or current 
offspring adiposity. Maternal pre-pregnancy overweight/obesity is associated with impaired 
offspring glucose regulation, which is explained by confounders and/or current adiposity. 
We measured cardio-metabolic markers in offspring of mothers with GDM, pre-pregnancy overweight 
and controls. GDM was, unlike maternal overweight, linked with an unhealthier cardio-metabolic 
profile. 
Introduction 
Metabolic abnormalities, including alterations in lipid and carbohydrate metabolism, are 
likely among women with gestational diabetes (GDM), overweight (body mass index, BMI ≥ 
25kg/m2) or obesity (BMI ≥ 30kg/m2) during pregnancy. At a critical period of fetal 
development, exposure to e.g. hyperglycemia, may induce long-term impacts on the fetus by 
creating a metabolic memory, previously described as fetal programming (1). Prenatal 
exposure to a hyperglycemic environment is known to alter growth trajectories and 
homeostatic regulatory mechanisms, and these changes predispose offspring to epigenetic 
changes (2, 3). It is likely that both maternal GDM and overweight/obesity provide a prenatal 
environment making the fetus susceptible to adverse in utero programming. This may cause 
increased risk of next-generation overweight and obesity, and result in an intergenerational 
cycle of obesity and insulin resistance. 
Offspring of mothers with GDM show markers of insulin resistance and metabolic 
syndrome, higher BMI and waist circumference by adolescence (4). Further, adult offspring 
of mothers with GDM represent a risk group for overweight and metabolic syndrome (5). 
Exposure to maternal obesity during pregnancy also affects offspring health, particularly 
with increased risk for obesity and metabolic sequelae (6). In a recent review by Nicholas et 
al. maternal obesity increased offspring risk of both obesity and insulin resistance in 
childhood, adolescence and adulthood (7). Previous studies have also linked high maternal 
pre-pregnancy BMI to unfavorable offspring body composition in infancy (8), childhood (9), 
adolescence (10) and young adulthood (11). Even at a mean age of 62 years a less favorable 
AD
VA
N
CE
 A
RT
IC
LE
:
TH
E 
JO
UR
NA
L 
O
F 
CL
IN
IC
AL
 
EN
D
O
CR
IN
O
LO
G
Y 
& 
M
ET
AB
O
LI
SM
JC
EM
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/advance-article-abstract/doi/10.1210/jc.2018-02743/5368422 by N
ational Library of H
ealth Sciences user on 07 M
arch 2019
AD
VA
NC
E 
AR
TI
CL
E
The Journal of Clinical Endocrinology & Metabolism; Copyright 2019  DOI: 10.1210/jc.2018-02743 
 
 
3
body composition and higher BMI in the offspring has been reported (12). However, it is not 
always clear to what extent the associations represent genetic or lifestyle factors, shared by 
the family, and to what extent they represent causal programming effects. Moreover, it is 
uncertain to what extent these offspring consequences are a result of exposure to maternal 
GDM and to what extent maternal overweight/obesity. 
Despite previously well-established data on the strong influence of maternal pre-
pregnancy overweight/obesity or GDM on offspring’s increased risk for obesity and 
metabolic sequelae during childhood, it is less clear whether the effects extend into adult age. 
Taking these observations together, we hypothesized that maternal GDM and pre-
pregnancy overweight/obesity may affect cardio-metabolic risk factors in adult offspring. In 
this study, we investigate the impact of exposure to maternal GDM or pre-pregnancy 
overweight/obesity on adult offspring cardio-metabolic health. 
Materials and Methods 
Participants 
Participants of the current study come from two prospective birth cohorts (Figure 1) (11): the 
ESTER Maternal Pregnancy Disorders Study and the Arvo Ylppö Longitudinal Study 
(AYLS). 
The ESTER Study consists of two arms (Figure 1): 1) ESTER Preterm Birth (13) and 2) 
ESTER Maternal Pregnancy Disorders arms. The present study is based on the latter arm. All 
ESTER study participants were born in the two northernmost provinces of Finland. Those 
born in 1985–1986 were recruited from the Northern Finland Birth Cohort 1986 (NFBC 
1986) (14) and those born in 1987–1989 through the Finnish Medical Birth Register (FMBR) 
(13), as previously described (15). We selected all participants of the ESTER Maternal 
Pregnancy Disorders arm who were confirmed to have maternal GDM (n=157), regardless of 
the mother’s pre-pregnancy BMI. Among ESTER clinical study participants invited as 
controls (15), participants were stratified into two groups: one group with maternal pre-
pregnancy overweight/obesity included offspring born at term to mothers with pre-pregnancy 
BMI ≥ 25kg/m2 and no GDM (n=44), while the control group constituted the remaining 
controls, all with maternal pre-pregnancy BMI < 25kg/m2 and no GDM (n=281). 
All AYLS participants (Figure 1) were born in the province of Uusimaa, in Southern 
Finland between 1985 and 1986. This cohort consists of all live-born infants admitted to 
neonatal wards in obstetric units, or transferred to the neonatal intensive care unit of the 
Children’s Hospital, Helsinki University Central Hospital within 10 days of their birth, with 
the population ranging from severely ill preterm infants to infants born at term, requiring only 
brief inpatient observation, and their controls, as previously described (16, 17). Of these 
AYLS cohort participants, with data available, we selected 1) all who were exposed to 
maternal GDM, at any maternal BMI (n=37), 2) those who had maternal BMI ≥ 25kg/m2 and 
no GDM (n=109) and 3) controls (i.e. originally recruited as controls, maternal BMI < 
25kg/m2 and no GDM; n=266). 
For all study participants, perinatal data were collected from healthcare records and 
questionnaires. Length of gestation, maternal GDM, hypertension (gestational or chronic) and 
preeclampsia (including superimposed) diagnoses were independently confirmed according 
to prevailing criteria by reviewing original hospital records (4, 18). Maternal GDM was 
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screened for and diagnosed by oral glucose tolerance test (OGTT). Screening was performed 
in the maternal welfare clinics between 26 and 28 gestational weeks. Indications for 
screening were glucosuria, prior GDM, suspected fetal macrosomia, previous macrosomic 
infant (birth weight >4,500 g), maternal pre-pregnancy BMI ≥ 25 kg/m2, and maternal age ≥ 
40 years. The OGTT was performed after overnight fasting by using a 75-g oral glucose load. 
At the time of diagnosis in the 1980s, the following cutoff limits for GDM were used for 
venous blood glucose: >5.5 mmol/l at fasting, >11.0 mmol/l and >8.0 mmol/l, 1 hour and 2 
hours after the glucose load, respectively. According to prevailing national guidelines, a 
diagnosis of GDM required a minimum of one abnormal value in the OGTT (4). For 
comparison, the International Association of Diabetes and Pregnancy Study Groups 
(IADPSG) Consensus Panel diagnostic criteria used today are set at fasting plasma glucose 
≥5.1mmol/l, and ≥10.0 mmol/l and ≥8.5 mmol/l following a 75g oral glucose load (19). 
Offspring to mothers with type 1 (n=28) or 2 diabetes (n=1) were excluded from all 
analyses. We further excluded subjects who were pregnant (n=9) during the clinical 
examination, reported having cerebral palsy (n=8), mental disability (n=11) or severe 
physical disability (n=5), as these conditions might affect the measured outcomes. We 
categorized all ESTER and AYLS cohort participants who underwent biochemical measures 
into three groups: 1) offspring of mothers with GDM (OGDM) at any level of maternal BMI, 
2) offspring of normoglycemic mothers with pre-pregnancy overweight/obesity (ONO) and 
3) controls, i.e. offspring of mothers with pre-pregnancy BMI < 25kg/m2 and no GDM. As a 
result, 906 subjects were included in the analyses; OGDM n = 193, ONO n= 157 and 556 
controls. 
Ethics 
Our study protocol was in accordance with the Declaration of Helsinki. It was approved by 
the Ethics Committees of the University of Oulu, the Helsinki City Maternity Hospital, the 
Helsinki University Central Hospital and Jorvi Hospital, the Ethics Committee of the 
Northern Ostrobothnia Hospital District and the Coordinating Ethics Committee of the 
Helsinki and Uusimaa Hospital District. Written informed consent was obtained from all 
participants. Because of individual participant consent, these data are not freely available. 
Researchers requesting data access are asked to contact the corresponding author. Requests 
may be subject to ethics review and/or participant’s re-consent. 
Measures and procedures 
Anthropometry was measured during clinical examinations conducted in 2009-2011 for 
ESTER participants and during 2009-2012 for AYLS participants. Height was measured 
three times without socks and shoes, with a portable stadiometer. Weight was measured 
during the clinical visit. Most of our participants also underwent bioimpedance measurement 
and the bioimpedance devise (InBody 3.0, Biospace Co., Ltd., Seoul, Korea) contains a scale. 
For individuals who did not undergo bioimpedance we used an electronic scale. BMI was 
calculated using means of the repeated measurements [weight (kg) / height squared (m2)]. 
All participants attended a clinical visit in the morning, after an overnight fast. They were 
examined by a trained study nurse. After a 5-minute rest in a sitting position, blood pressure 
was measured 3 times from the right upper arm using an automatic oscillometric blood 
pressure monitor (Omron M10-IT Intellisense, Omron Healthcare Co., Kyoto, Japan). All 
participants completed questionnaires regarding both participant and parental health status, 
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including medical history and medications. Data on highest parental educational attainment 
were enquired and categorized into four levels (dummy coded) to serve as an indicator of 
childhood socioeconomic status. 
Laboratory analyses  
At the clinical visit venous blood samples were taken in a sitting position with a light stasis 
into a fluoride-citrate tube (Venosafe, Terumo Europa, Leuven, Belgium) for glucose assays 
and into a tube containing clot activator (Venosafe) for other assays. Fluoride-citrate plasma 
and serum were separated by centrifuging, frozen locally immediately after separation, and 
then transported frozen on dry ice to the biochemistry laboratory of the Genomics and 
Biomarker Unit (former the Disease Risk Unit) at National Institute for Health and Welfare 
(Helsinki, Finland) and the Oulu University Hospital laboratory. All analyses were performed 
on a clinical chemistry analyzer (Architect ci8200 Abbott Laboratories, Abbott Park, Illinois, 
USA) at the biochemistry laboratory in the AYLS and ESTER studies, except for fasting 
plasma glucose, total cholesterol (TC), high- and low-density lipoprotein cholesterol (HDL-C 
and LDL-C), triglycerides (TGs), alanine aminotransferase (ALT), aspartate transaminase 
(AST), gamma glutamate (GT) and uric acid regarding ESTER study participants. In the 
ESTER study these samples were analyzed by using an Advia 2400 automatic chemical 
analyzer (Siemens Diagnostics, Terrytown, NY, USA) at Oulu University Hospital 
laboratory, and have been described in detail previously (13) (freely available as web 
appendix). 
For standardizing measurements, the biochemistry laboratory has taken part in Lipid 
Standardization Program organized by Centers for Disease Control and Prevention (CDC, 
Atlanta, Georgia, USA) and External Quality Assessment Schemes organized by Labquality 
(Helsinki, Finland). During the course of the studies, the between-assay coefficient of 
variation (CV%, mean ±SD), systematic error (Bias%, mean ±SD) and the principle of the 
methods in the biochemistry laboratory are shown in Supplementary Table 1 (20). 
Statistical analyses 
All statistical analyses were conducted with IBM SPSS Statistics versions 24 and 25 (SPSS 
Inc., Chicago, IL, USA). Analyses were performed in a combined dataset of both birth 
cohorts (ESTER and AYLS). We compared descriptive characteristics between participants 
with t-test (continuous variables) and χ2-test (categorical variables). The significance level 
was set to two-tailed P < 0.05. As the biochemical measures were not normally distributed, 
we log-transformed them prior to statistical analyses, to attain normality. We used multiple 
linear regression models to compare cardio-metabolic biochemical measures, blood pressure 
and heart rate between adult offspring of mothers with GDM or pre-pregnancy 
overweight/obesity with controls. We adjusted for age, sex and birth cohort in model 1. 
Prenatal and parental confounders were taken into account in model 2, as we additionally 
adjusted for gestational age, birth weight SD score, maternal hypertension or preeclampsia 
during pregnancy, maternal smoking during pregnancy, parental educational attainment, 
parental history of hypertension, diabetes, stroke or myocardial infarction. Participant related 
factors, including age, sex, birth cohort, BMI, height and daily smoking were adjusted for in 
model 3. Finally, in the full model 4, all the above mentioned covariates were included. 
Results 
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Perinatal and current characteristics and parental medical history of the OGDM, ONO and 
control groups are presented in Table 1. For comparison, these data are also shown separately 
for the two source cohorts in Supplementary Table 2 (20). Mean age of offspring at 
assessment was 24.1 years (SD 1.3) and 51.3 % were women. Among offspring, 2 OGDM, 2 
ONO and 8 controls were born from twin pregnancies, the remainder were all singletons. As 
a sensitivity analysis, we excluded all twins and reran all analyses. This did not affect our 
results. Cardio-metabolic biochemical measures, heart rate and blood pressure of the 
offspring, with corresponding reference or target values are presented in Table 2. 
Cardio-metabolic markers in offspring of mothers with gestational diabetes (Table 3) 
There were clear associations between maternal GDM and adult offspring cardio-metabolic 
markers. Fasting glucose and insulin were higher in OGDM compared with controls, 
although adjusting for confounders and current offspring characteristics including BMI 
attenuated these differences to non-significance (Table 3, Supplementary Table 3) (20). 
Further, OGDM had lower sex hormone binding globulin (SHBG) in both OGDM-men and 
OGDM-women. Also HDL-C, Lipoprotein (a) (Lp(a)) and Apolipoprotein A1 (ApoA1) were 
lower; apart from Lp(a), these differences survived adjustment for confounders and current 
characteristics. No statistically significant differences were seen in heart rate, testosterone, 
LDL-C, TGs, Apolipoprotein B (ApoB), free fatty acid (FFA), uric acid or liver tests (ALT, 
AST, GT). In model 1, TC and blood pressure was similar between OGDM and controls, 
while after adjusting for confounders and current characteristics TC, systolic and diastolic 
blood pressures were slightly lower in OGDM (Table 3, Supplementary Table 3) (20).  
We further reran all analyses, replacing BMI and height with lean body mass and fat 
percentage in models 3 and 4 (data not shown). The results remained similar for model 3. In 
model 4, our findings of lower FFA [-9.2% ((-17.6, -0.1)] and hsCRP [-23.2 (-40.3, -1.1)] in 
OGDM both reached statistical significance. 
To further distinguish between effects of maternal GDM and maternal overweight/obesity 
on adult offspring cardiovascular risk factors, we reran all analyses separately comparing 
offspring to mothers with 1) GDM and pre-pregnancy BMI < 25kg/m2 (n=115) 2) GDM and 
pre-pregnancy BMI ≥ 25kg/m2 (n=71) with controls (n=556). Most of our results remained 
similar (Supplementary Table 4) (20). A combination of maternal GDM and 
overweight/obesity showed a greater effect on fasting glucose and insulin than maternal 
overweight/obesity alone. Adjusting for confounders attenuated these differences between 
groups and this was largely due to offspring BMI as a mediator in OGDM with maternal BMI 
≥ 25 kg/m2. 
Cardio-metabolic markers in offspring of mothers with overweight/obesity (Table 3) 
Associations found between maternal pre-pregnancy overweight/obesity and adult offspring 
cardio-metabolic markers were mostly explained by current offspring characteristics and 
confounders. Fasting glucose and insulin were both higher in ONO vs. controls, these 
findings disappeared after adjustments in models 2-4 (Table 3, Supplementary Table 3) (20). 
In men, serum testosterone was lower in model 1, also this difference attenuated after 
adjustments in models 2-4. All other cardio-metabolic markers, including heart rate, SHBG, 
FFA, TC, HDL-C, LDL-C, TGs, LPa, ApoA1, ApoB, liver tests and uric acid were similar 
between ONO and controls. Only in model 2, hsCRP was higher in the ONO group, 
adjustment for confounders diluted this finding. However, although systolic blood pressure 
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was not different between groups in model 1, it was somewhat lower in models 2-4 in ONO-
participants (Table 3, Supplementary Table 3) (20).  
As with OGDM, we also reran all analyses comparing ONO vs. controls, replacing BMI 
and height with lean body mass and fat percentage in models 3 and 4. No changes were seen 
in the results (data not shown). 
We further reran all analyses separately comparing offspring to mothers with pre-
pregnancy BMI ≥ 30kg/m2 (n=28) vs. controls. Most results remained similar (data not 
shown). However, in model 1, hsCRP [66.2% (95% CI. 3.6, 166.3)], TGs [21.5% (95% CI: 
2.3, 44.3)] and ApoB [10.8% (95% CI: 0.1, 22.7)] were all higher in in offspring exposed to 
maternal pre-pregnancy obesity compared with controls. Further, in model 1, heart rate was 
lower [-5.5% (95%CI: -10.0, -1.0)] and fasting plasma glucose similar [-1.3% (95% CI:-4.3, 
1.7)] between obesity exposed and controls. After full adjustment (model 4) all results were 
similar with ONO vs. controls regarding all cardio-metabolic markers (data not shown). 
Discussion 
We combined data from two longitudinal birth cohorts to study common cardio-metabolic 
markers in the adult offspring of mothers with GDM or overweight/obesity at start of 
pregnancy. There are two main findings in this study. First, maternal GDM was associated 
with increased insulin resistance and risk for an atherogenic lipid profile in adult offspring. 
Some, but not all, of this association was explained by confounding factors or current 
offspring characteristics including adiposity. Second, in offspring of mothers with pre-
pregnancy overweight/obesity without GDM the consequences were not as clear. They had 
higher fasting glucose and insulin than controls, in part explained by parental and prenatal 
confounders or adult BMI or body fat percentage, but similar levels of other cardio-metabolic 
markers. This pattern differs from that of body composition. In this same cohort exposure to 
both maternal GDM and overweight/obesity was associated with higher offspring fat 
percentage and waist circumference, with stronger associations found related to maternal 
overweight/obesity (11). 
Our findings of higher fasting glucose and insulin in OGDM compared with controls, 
attenuated to non-significance after adjusting for confounders and current characteristics. To 
further differentiate between the effects of maternal GDM and maternal overweight/obesity 
on offspring cardio-metabolic health, we divided OGDM participants into two subgroups 
based on maternal pre-pregnancy weight (BMI < 25 kg/m2 and BMI ≥ 25 kg/m2). A 
combination of maternal GDM and overweight/obesity showed a greater effect on fasting 
glucose and insulin than maternal overweight/obesity alone. In the fully adjusted model, the 
adjustments attenuated these differences in fasting glucose and insulin; this attenuation was 
largely due to offspring BMI as a mediator in OGDM with maternal BMI ≥ 25 kg/m2. 
Further, we report an atherogenic lipid profile in OGDM vs. controls, based on lower 
HDL-C and ApoA1 in OGDM. ApoA1 is a major component of HDL-C and low levels of 
ApoA1 are a well established risk factor of atherosclerosis. 
In addition to the commonly measured indicators, we found lower SHGB in both OGDM-
men and OGDM-women. SHBG is a measure of insulin resistance and hyperandrogenism, 
and this may reflect increased cardio-metabolic risk later in life. 
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Traditionally, the global obesity epidemic has been explained by an increase in 
availability and consumption of energy-dense foods and a simultaneous reduction in physical 
activity. However, other factors behind this rise in obesity prevalence exist, including genetic 
factors, an adverse intrauterine milieu and epigenetic changes this milieu may provoke (2). 
GDM is a common cause of such an adverse milieu and may cause epigenetic changes in 
offspring. For instance, in a GDM mice model, offspring exposed to GDM showed altered 
DNA methylation patterns in the pancreas, and this phenotype was characterized by 
dyslipidemia, insulin resistance and glucose intolerance (3). Our findings suggest that 
maternal GDM and pre-pregnancy overweight without diagnosed GDM may have distinct 
effects on offspring health. Previous studies have shown robust associations between higher 
maternal pre-pregnancy BMI and offspring adiposity as indicated by increased fat mass, fat-
free mass and percentage of body fat in both neonates (8), and 6-7 year old children (9); 
higher BMI and greater waist circumference at adolescence (10), higher BMI, waist 
circumference, fat mass and fat percentage in young adulthood (11) and higher fat mass and 
BMI at older age (12). As for pre-pregnancy BMI and offspring cardio-metabolic risk factors, 
Gaillard et al reported an adverse cardio-metabolic profile (including lipid levels, glucose, 
insulin, homeostatic model assessment of insulin resistance) in 1392 adolescents at mean age 
17 years (21). These associations were independent of maternal GDM and largely mediated 
by adolescent BMI. In another study, including 1400 participants at 32 years of age, higher 
maternal pre-pregnancy BMI was associated with higher offspring blood pressure, insulin and 
triglycerides and lower HDL-C (22), again independent of maternal GDM and fully 
explained by current BMI of the offspring. This is consistent with our finding of higher 
fasting glucose and insulin among ONO who, however, had similar serum lipids and other 
biomarkers as controls. 
As to offspring of mothers with GDM, a previous study in 16-year-olds, in one of our 
source cohorts, showed that they have a higher BMI and waist circumference at adolescence 
than offspring of mothers without GDM (4). Further, in that study fasting insulin was higher 
and homeostatic model assessment-insulin sensitivity was lower in offspring to mothers with 
GDM, while blood lipids and glucose where similar to controls. To some extent maternal 
GDM is also associated with adult offspring body composition. In the same cohort 
participants, in which we now report on cardio-metabolic markers in the current study, higher 
fat percentages were seen in offspring exposed to GDM (11). As for maternal diabetes and 
offspring cardio-metabolic risk factors at adult age; recently a large Canadian cohort study 
including 467 850 mother-infant dyads, described an association between both maternal type 
2 diabetes (T2D) during pregnancy and GDM with T2D in offspring by age 30 (23). In this 
study exposure to maternal T2D during pregnancy conferred a greater risk to offspring 
compared with GDM exposure (3.19 vs. 0.80 cases of T2D per 1000 person-years) (23). In 
line with the Canadian study, we also showed increased markers of insulin resistance, i.e. 
higher fasting insulin and lower SHBG, HDL-C and ApoA1, in offspring with prenatal 
exposure to maternal GDM as compared to controls. 
Recently, Bellatorre et al reported an increase in liver fat, independent of offspring 
adiposity, in both childhood (mean age 10.4 years) and adolescence (mean age 16.4 years) in 
offspring of mothers with pre-pregnancy obesity (BMI ≥ 30 kg/m2), while no such effect was 
found in offspring of mothers with GDM (24). In our study we did not find any associations 
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between GDM or maternal pre-pregnancy overweight/obesity and biochemical markers of 
increased liver fat; levels of offspring liver enzymes were similar between groups. 
Strengths of our study include a rather large sample size and long follow-up time. One of 
the indications for screening GDM was having a pre-pregnancy BMI ≥ 25 kg/m2, thus 
mothers with GDM could be reliably separated from our group of normoglycemic mothers 
with overweight/obesity. To further distinguish between the effects of maternal GDM and 
maternal overweight/obesity on offspring cardio-metabolic health, we reran all analyses with 
OGDM participants further divided into two subgroups based on maternal pre-pregnancy 
weight (BMI < 25 kg/m2 and BMI ≥ 25 kg/m2 vs. controls). In these subgroup analyses with 
diminished numbers of participants, our results remained similar. Our participants come from 
an ethnically homogenous Finnish population, combined from two longitudinal study cohorts. 
The homogeneity of our study population may decrease the generalizability of our findings. 
Further, in the analyses we adjusted for important confounders, including perinatal and 
pregnancy related factors, parental hypertension, diabetes, stroke and myocardial infarction, 
and current participant related factors. However, residual confounding remains possible. Both 
treatment and GDM screening guidelines have changed during the previous 25 years. This 
may have introduced bias, depending on the adequacy of the screening. Thus, the GDM 
offspring in the current study may represent a more severe end of the GDM spectrum in 
today’s pregnant women. Unfortunately, we do not have data on maternal glucose levels 
throughout pregnancy. 
In sum, we found that maternal GDM is associated with increased levels of insulin 
resistance and a more atherogenic lipid profile in young adult offspring, as compared with 
controls. These findings suggest increased risk of cardio-metabolic diseases later in life. 
Maternal pre-pregnancy overweight or obesity alone was associated with offspring insulin 
resistance, but the association was weaker and explained by current adiposity. 
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Table 1. Baseline participant characteristics of adult offspring, exposed to maternal 
gestational diabetes (regardless of maternal BMI), maternal pre-pregnancy obesity or 
overweight but not gestational diabetes and their controls, i.e. offspring of normoglycemic 
mothers with normal pre-pregnancy weight. 
Characteristic Gestational P value b Pre- P value b Control 
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diabetes 
(n=193) 
pregnancy 
obesity or 
overweight 
a
, no 
gestational 
diabetes 
(n= 157) 
(n=556) 
Birth/Perinatal characteristics      
Maternal body mass index before pregnancy, mean (SD), kg/m2 24.9 (5.4) <0.001 28.0 (3.0) <0.001 21.2 (1.9) 
Twin pregnancy, n (%) 2 (1.3)  2 (1.3)  8 (1.4) 
Maternal hypertension, n (%) 52 (26.9) <0.001 53 (33.8) <0.001 73 (13.1) 
Maternal pre-eclampsia, n (%) 12 (6.2)  8 (5.1)  17 (3.1) 
Maternal smoking during pregnancy, n (%) 23 (11.9)  33 (21.0)  90 (16.2) 
Birth weight, mean (SD), g 3687 (626) <0.01 3458 (864)  3535 (465) 
Birth weight SD score, mean (SD) 0.55 (1.2) <0.001 0.09 (1.4)  -0.05 (0.9) 
Gestational age, mean (SD), weeks 39.0 (0.2) <0.001 39.1 (2.9) <0.001 39.9 (1.4) 
Small for gestational age, n (%) 1 (0.5)  15 (9.6) <0.001 8 (1.4) 
Large for gestational age, n (%) 26 (13.5) <0.001 10 (6.4) <0.01 10 (1.8) 
Male, n (%) 105 (54.4) <0.05 78 (49.7)  258 (46.4) 
Current characteristics      
Age, mean (SD), years 23.4 (1.3) <0.001 24.8 (1.1)  24.4 (1.3) 
Daily smoking, n (%) 55 (28.5) <0.05 52 (33.1)  141 (25.4) 
Body mass index, mean (SD), kg/m2      
Men 25.6 (4.7) <0.001 26.5 (4.8) <0.001 24.0 (3.6) 
Women 24.3 (4.4) <0.05 24.7 (4.6) <0.01 23.0 (4.2) 
Body mass index ≥ 25kg/m2, n (%) 81 (42.0) <0.01 78 (49.7) <0.001 158 (28.4) 
Body mass index ≥ 30kg/m2, n (%) 24 (12.4) <0.05 22 (14.0) <0.05 41 (7.4) 
Height, mean (SD), cm      
Men 178.9 (7.0)  178.0 (6.7)  178.9 (7.0) 
Women 165.9 (6.3)  164.7 (6.4)  165.2 (6.2) 
Parental education, n (%)  <0.05  <0.001  
Basic 28 (14.5)  21 (13.3)  30 (5.4) 
Secondary 101 (52.3)  83 (52.9)  281 (50.5) 
Lower-level tertiary 16 (8.3)  18 (11.5)  66 (11.9) 
Upper-level tertiary 46 (23.8)  28 (17.8)  165 (29.7) 
Maternal medical conditions at offspring mean age 24 years, n (%)      
Hypertension 42 (21.8) <0.001 50 (31.8) <0.001 52 (9.4) 
Diabetes 70 (36.3) <0.001 18 (11.5) <0.001 10 (1.8) 
Stroke or myocardial infarction 3 (1.6)  1 (0.6)  3 (0.5) 
Paternal medical conditions at offspring mean age 24 years, n (%)      
Hypertension 40 (20.1)  28 (17.8)  83 (14.9) 
Diabetes 16 (8.3)  23 (14.6)  43 (7.7) 
Stroke or myocardial infarction 13 (6.7)  3 (1.9)  19 (3.4) 
a Pre-pregnancy body mass index ≥ 25kg/m2 
b Linear regression model, adjusted for age, sex and source cohort, comparing offspring exposed to maternal 
gestational diabetes or maternal pre-pregnancy overweight/obesity with controls. All remaining p values are 
>0.05. 
Table 2. Cardio-metabolic markers of adult offspring, exposed to maternal gestational 
diabetes (regardless of maternal BMI), maternal pre-pregnancy obesity or overweight but not 
gestational diabetes and their controls, i.e. offspring of normoglycemic mothers with normal 
pre-pregnancy weight. 
Characteristic Gestational 
diabetes 
(n=193) 
Pre-
pregnancy 
obesity or 
overweight, 
no 
gestational 
diabetes 
Control 
(n=556) 
Reference 
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(n= 157) 
Fasting plasma glucose, mean (SD), mmol/l 5.2 (1.1) 5.2 (1.2) 5.1 (1.1) 4.2-6.0 
Fasting serum insulin, mean (SD), mU/l  10.3 (2.1) 22.8 (2.5) 14.8 
(2.6) 
2.0-20 
Total cholesterol, mean (SD), mmol/l 4.5 (1.2) 4.7 (1.2) 4.6 (1.2) < 5.0 
HDL cholesterol, mean (SD), mmol/l 1.4 (1.3) 1.5 (1.3) 1.6 (1.3) > 1.0 / > 1.2a 
LDL cholesterol, mean (SD), mmol/l 2.7 (1.4) 2.7 (1.3) 2.6 (1.3) < 3.0 
Triglycerides, mean (SD), mmol/l 1.0 (1.6) 1.0 (1.6) 0.9 (1.6) < 1.7 
Lipoprotein (a), mean (SD), mg/l 78.8 (3.1) 99.0 (3.3) 95.1 
(3.1) 
< 250 
Apolipoprotein A1, mean (SD), g/l 1.4 (1.2) 1.5 (1.2) 1.5 (1.2) 1.0-2.0 / 1.1-2.3a 
Apolipoprotein B, mean (SD) g/l 0.7 (1.3) 0.8 (1.3) 0.7 (1.3) 0.66-1.33 / 0.60-
1.17a 
Serum free fatty acid, mean, (SD), mmol/l 0.5 (1.6) 0.5 (1.5) 0.5 (1.6) 0.08-0.7 
Serum sex hormone binding globulin, (SD) nmol/l     
Men  28.6 (1.5) 31.0 (1.5) 32.4 
(1.5) 
14-71 
Women  100.2 (2.4) 126.1 (2.6) 137.3 
(2.3) 
20-155 
Serum testosterone, (SD), nmol/l     
Men  18.4 (1.4) 17.6 (1.6) 19.7 
(1.4) 
10-38 
Women  1.3 (1.4) 1.3 (1.4) 1.3 (1.4) 0.4-2 
Plasma uric acid, mean (SD), µmol/l 290.1 (1.6) 286.4 (1.3) 279.7 
(1.3) 
230-480 / 155-400a 
High-sensitivity C-reactive protein, mean (SD), mg/l 1.0 (3.5) 1.2 (3.3) 1.0 (3.7) 0.2-3 
Plasma alanine aminotransferase, mean (SD), U/l 23.0 (1.7) 21.9 (1.8) 21.1 
(1.7) 
< 50 / < 35a 
Plasma aspartate transaminase, mean (SD), U/l 22.5 (1.4) 24.7 (1.4) 23.3 
(1.4) 
15-45 / 15-35a 
Plasma gamma glutamate, mean (SD), U/l 19.2 (1.8) 20.2 (1.8) 18.0 
(1.7) 
< 60 / < 40a 
Systolic blood pressure, mean (SD), mmHg 119.4 
(14.3) 
126.2 (16.4) 122.6 
(15.0) 
<130 
Diastolic blood pressure, mean (SD), mmHg 75.1 (7.5) 76.8 (8.9) 76.0 
(8.1) 
<85 
Heart rate, mean (SD), beats/min 71.0 (13.0) 74.2 (14.0) 72.7 
(12.1) 
60-80 
Means other than blood pressure and pulse are geometric means. The geometric mean is the nth root of the 
product of n values. Geometric standard deviations correspond to the percentage increase in a variable 
corresponding to one standard deviation unit change in the logarithm of the variable. 
Statistical comparisons among the three groups are shown in Table 3. 
a 
men/women 
Table 3. Cardio-metabolic markers of young adults born to mothers with gestational diabetes 
(regardless of maternal BMI) compared with controls, comprising offspring of 
normoglycemic mothers with normal pre-pregnancy weight, and offspring of mothers with 
pre-pregnancy obesity or overweight but no gestational diabetes, compared with controls. 
 Controls 
(n=556) 
Maternal gestational diabetes 
(n=193) 
Maternal pre-pregnancy 
obesity or overweight, no 
gestational diabetes  (n=157) 
Characteristic/Measure and model Mean 
(SD) 
Mean 
differencea 
95 % 
Confidenc
e interval 
P 
value 
Mean 
difference
a 
95 % 
Confiden
ce 
interval 
P 
value 
Fasting plasma glucose, mmol/l 5.1 (1.1)   
 
   
1  1.6 0.1, 3.1 0.03 2.3 0.5, 4.3 0.01 
4  0.4 -1.3, 2.2 0.62 0.4 -1.5, 2.3 0.69 
Fasting serum insulin, mU/l 14.8 (2.6)       
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1  12.7 4.4, 21.9 0.002 8.7 0.2, 17.8 0.05 
4  8.4 -0.1, 17.6 0.05 -3.1 -10.7, 5.0 0.44 
Serum testosterone in men, nmol/l 19.7 (1.4)       
1  -7.9 -15.2, 0.2 0.06 -10.1 -18.4, -0.9 0.03 
4  -7.3 -15.9, 2.1 0.12 -6.1 -15.4, 4.2 0.23 
Serum testosterone in women, nmol/l 1.3 (1.4)       
1  0.2 -8.6, 9.7 0.97 1.0 -7.7, 10.6 0.83 
4  3.8 -7.0, 15.8 0.51 0.5 -9.4, 11.5 0.92 
Serum sex hormone binding globulin in men, 
nmol/l 
32.4 (1.5)       
1  -12.4 -20.2, -3.9, 0.005 -3.9 -13.3, 6.5 0.45 
4  -10.3 -19.2, -0.5 0.04 2.7 -7.9, 14.6 0.63 
Serum sex hormone binding globulin in women, 
nmol/l 
137.3 
(2.3) 
      
1  -33.2 -46.3, -16.8 0.0003 -3.3 -22.3, 20.3 0.76 
4  -36.6 -50.9, -18.0 0.001 2.0 -20.4, 30.6 0.88 
Serum free fatty acid, mmol/l 0.5 (1.6)       
1  -3.6 -11.0, 4.5 0.37 3.9 -4.1, 12.6 0.35 
4  -6.9 -15.5, 2.5 0.15 2.2 -6.7, 12.0 0.64 
Total cholesterol, mmol/l 4.6 (1.2)       
1  -2.9 -6.5, 0.9 0.14 1.9 -3.9, 8.1 0.53 
4  -3.9 -7.5, -0.2 0.04 -0.3 -4.0, 3.6 0.88 
HDL cholesterol, mmol/l 1.6 (1.3)       
1  -6.6 -10.9, -2.2 0.004 -0.6 -7.3, 6.5 0.86 
4  -5.4 -9.4, -1.0 0.02 -1.8 -5.8, 2.4 0.40 
LDL cholesterol, mmol/l 2.6 (1.3)       
1  -1.4 -7.5, 5.2 0.67 2.6 -6.9, 13.1 0.59 
4  -4.0 -9.8, 2.0 0.19 0.2 -5.5, 6.3 0.95 
Triglycerides, mmol/l 0.9 (1.6)       
1  5.5 -3.7, 15.8 0.25 6.5 -7.1, 22.1 0.36 
4  0.0 -8.8, 9.6 0.98 -1.0 -9.6, 8.3 0.82 
Lipoprotein (a) mg/l 95.1 (3.1)       
1  -18.9 -33.9, -0.4 0.05 4.3 -16.1, 29.4 0.70 
4  -10.1 -30.0, 15.5 0.40 6.3 -17.1, 36.3 0.63 
Apolipoprotein A1, g/l 1.5 (1.2)   
 
   
1  -4.5 -7.5, -1.4 0.005 -2.7 -5.6, 0.4 0.09 
4  -4.6 -8.1, -1.0 0.01 -2.0 -5.2, 1.4 0.25 
Apolipoprotein B, g/l 0.7 (1.3)       
1  -1.6 -6.1, 3.1 0.50 -0.1 -2.3, 2.1 0.91 
4  -4.5 -9.5, 0.9 0.10 0.3 -4.6, 5.4 0.91 
Plasma uric acid, µmol/l 279.7 
(1.3) 
      
1  4.5 -2.8, 12.2 0.23 2.9 -1.9, 8.0 0.23 
4  -2.9 -8.4, 3.1 0.35 -2.8 -6.7, 1.2 0.17 
High-sensitivity C-reactive protein, mg/l 1.0 (3.7)       
1  -14.6 -33.6, 9.7 0.22 -4.3 -33.9, 38.7 0.82 
4  -17.0 -35.8, 7.4 0.16 16.4 -8.7, 48.6 0.22 
Plasma alanine aminotransferase, U/l 21.1 (1.7)       
1  4.5 -4.9, 14.8 0.36 13.2 -2.0, 30.7 0.09 
4  -1.7 -10.4, 8.0 0.72 -1.9 -10.6, 7.8 0.70 
Plasma aspartate transaminase, U/l 23.3 (1.4)       
1  1.9 -4.9, 9.3 0.60 3.9 -7.0, 16.2 0.50 
4  1.6 -5.0, 8.7 0.64 0.2 -6.2, 7.0 0.95 
Plasma gamma glutamate, U/l 18.0 (1.7)       
1  4.9 -4.6, 15.4 0.32 7.8 -6.2, 24.0 0.29 
4  -1.3 -10.5, 8.9 0.79 -0.3 -9.2, 9.6 0.96 
Systolic blood pressure, mmHga 122.6 
(15.0) 
      
1  -0.9 -2.7, 1.0 0.36 0.0 -2.0, 2.0 1.0 
4  -3.6 -5.7, -1.5 0.001 -3.5 -5.7, -1.4 0.001 
Diastolic blood pressure, mmHga 76.0 (8.1)       
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1  -0.9 -2.2, 0.5 0.21 0.4 -1.0, 1.9 0.61 
4  -2.2 -3.8, -0.7 0.006 -1.6 -3.2, 0.0 0.05 
Heart rate, beats/mina 72.7 
(12.1) 
      
1  -1.2 -3.3, 0.9 0.27 1.4 -0.8, 3.6 0.21 
4  -1.0 -3.5, 1.5 0.41 1.1 -1.5, 3.6 0.41 
a Mean differences for blood pressures are expressed as mmHg, and for heart rate as beats/min while the 
remaining results are presented as % difference. 
Multiple linear regression models as follows: 
Model 1 adjusted for age, sex and source cohort 
Model 4 adjusted for age, sex, source cohort, gestational age, birth weight standard deviation score, maternal 
hypertension or preeclampsia during pregnancy, maternal smoking during pregnancy, parental educational 
attainment and parental hypertension, diabetes, stroke or myocardial infarction, body mass index, height and 
daily smoking 
Models 2 and 3 are shown in Supplementary Table 3. 
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ESTER study
AYLS study
Invited through Northern
Finland Birth Cohort
(NFBC) 1986
n=1505
Invited through Finnish
Medical Birth Register
(FMBR) 1987-1989 
n=1415
All ESTER participants born at term with 
confirmed maternal gestational diabetes 
(GDM) exposure n=156
Maternal pre-pregnancy BMI ≥25kg/m2, no 
GDM n=48
Controls n=290
Underwent biochemical measures, n=906
GDM exposed n=193 
Maternal BMI ≥ 25kg/m2 and GDM unexposed n=157
Controls n=556
All deliveries in 7 
maternity hospitals in 
Uusimaa Province, 
Finland during March
1985-March 1986
n=15311
Admitted to 
neonatal
wards
within 10 
days after
birth
n=1535
Healthy
controls
born after
every
second
infant
admitted to 
ward n=658
Not traced
n=280
Invited to participate in a 
clinical examination
n=1913
Participated in AYLS 
study n=1136
Perinatal data 
not accessible
n=237
Maternal GDM n=37
Maternal pre-pregnancy BMI 
≥25kg/m2, no GDM n=109
Controls n=266
Participated in the 
ESTER study n=1161 
(includes preterm, 
maternal gestational
diabetes, gestational
hypertension, 
preeclampsia and 
control groups)
ESTER Preterm
Birth Study arm
n=753
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